Gefitinib Plus Chemotherapy Versus Gefitinib Alone in Untreated EGFR-Mutant  Non-Small Cell Lung Cancer Patients with Brain Metastases (GAP BRAIN): An Open-Label, Randomized, Multicenter, Phase 3 Study

[1]  A. Wozniak,et al.  Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data , 2016, Cancer.

[2]  D. Costa,et al.  Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. , 2015, Lung cancer.

[3]  M. Shingyoji,et al.  Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. , 2013, Lung cancer.

[4]  Li Zhang,et al.  Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. , 2013, The Lancet. Oncology.

[5]  Yi-long Wu,et al.  Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Dae-Ho Lee,et al.  Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. , 2012, Lung Cancer.

[7]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[8]  Frank Winkler,et al.  Brain metastases: pathobiology and emerging targeted therapies , 2012, Acta Neuropathologica.

[9]  F. Barlesi,et al.  Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  R. Jain,et al.  The biology of brain metastases—translation to new therapies , 2011, Nature Reviews Clinical Oncology.

[11]  V. Guillem,et al.  Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation , 2010, European Respiratory Journal.

[12]  A. Gemma,et al.  F1000 highlights , 2010 .

[13]  R. Talamini,et al.  Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. , 2010, Lung cancer.

[14]  E. Dunbar,et al.  Modern Multidisciplinary Management of Brain Metastases , 2010, Current oncology reports.

[15]  C. Obasaju,et al.  Outcomes Associated with Brain Metastases in a Three-Arm Phase III Trial of Gemcitabine-Containing Regimens Versus Paclitaxel Plus Carboplatin for Advanced Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  L. Recht,et al.  Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. , 2009, International journal of radiation oncology, biology, physics.

[17]  E. Giovannetti,et al.  Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells , 2008, Molecular Pharmacology.

[18]  R. Perez-soler,et al.  Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non–Small Cell Lung Cancer Cells , 2007, Clinical Cancer Research.

[19]  M. Millward,et al.  A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. , 2004, Lung cancer.

[20]  W. Curran,et al.  Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Antonadou,et al.  Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.